Evidence map›Paper›PMID 31154431›Full record

ArticleHeart (British Cardiac Society)2019

Higher left ventricular mass-wall stress-heart rate product and outcome in aortic valve stenosis.

Eva Gerdts, Sahrai Saeed, Helga Midtbø, Anne Rossebø, John Boyd Chambers, Eigir Einarsen, Edda Bahlmann, Richard Devereux

Open access · hybridAbstract read
In one paragraph

Article in Heart (British Cardiac Society), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 6 countries.

Eva GerdtsDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0003-4109-2311
Sahrai SaeedDepartment of Heart Disease, Haukeland Universitetssjukehus, Bergen, Norway.
Helga MidtbøDepartment of Heart Disease, Haukeland Universitetssjukehus, Bergen, Norway.
Anne RossebøCardiology Department, Oslo University Hospital, Ullevål, Norway.
John Boyd ChambersGuys and St Thomas Hospital, London, UK.
Eigir EinarsenDepartment of Clinical Science, University of Bergen, Bergen, Hordaland, Norway.
Edda BahlmannCardiology, Asklepios Clinic St. Georg, Hamburg, Germany.ORCID 0000-0002-4242-0535
Richard DevereuxNewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA.
Haukeland University Hospital · NOUniversity of Bergen · NOAsklepios Klinik St. Georg · DENewYork–Presbyterian Hospital · USOslo University Hospital · NOSt Thomas' Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWhether increased myocardial oxygen demand could help explain the association of left ventricular (LV) hypertrophy with higher adverse event rate in patients with aortic valve stenosis (AS) is unknown.

methodsData from 1522 patients with asymptomatic mostly moderate AS participating in the Simvastatin-Ezetimibe in AS study followed for a median of 4.3 years was used. High LV mass-wall stress-heart rate product was identified as >upper 95% CI limit in normal subjects. The association of higher LV mass-wall stress-heart rate product with major cardiovascular (CV) events, combined CV death and hospitalised heart failure and all-cause mortality was tested in Cox regression analyses, and reported as HR and 95% CI.

resultsHigh LV mass-wall stress-heart rate product was found in 19% at baseline, and associated with male sex, higher body mass index, hypertension, LV hypertrophy, more severe AS and lower LV ejection fraction (all p<0.01). Adjusting for these confounders in time-varying Cox regression analysis, 1 SD higher LV mass-wall stress-heart rate product was associated with higher HR of major CV events (HR 1.16(95% CI 1.06 to 1.29)), combined CV death and hospitalised heart failure (HR 1.29(95% CI 1.09 to 1.54)) and all-cause mortality (HR 1.34(95% CI 1.13 to 1.58), all p<0.01).

conclusionIn patients with initially mild-moderate AS, higher LV mass-wall stress-heart rate product was associated with higher mortality and heart failure hospitalisation. Our results suggest that higher myocardial oxygen demand is contributing to the higher adverse event rate reported in AS patients with LV hypertrophy. TRIAL REGISTRATION NUMBER: NCT000092677;Post-results.

Indexed as

Heart RateOxygen ConsumptionVentricular Function, LeftVentricular RemodelingAgedAortic ValveAortic Valve StenosisDisease ProgressionFemaleHeart FailureHumansHypertrophy, Left VentricularMaleMiddle AgedMyocardiumPrognosisaortic stenosisechocardiographyhypertension

Identifiers

PMID31154431
PMCPMC6855785
OpenAlexW2947098143

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.